2v3e
From Proteopedia
| Line 1: | Line 1: | ||
[[Image:2v3e.png|left|200px]] | [[Image:2v3e.png|left|200px]] | ||
| - | <!-- | ||
| - | The line below this paragraph, containing "STRUCTURE_2v3e", creates the "Structure Box" on the page. | ||
| - | You may change the PDB parameter (which sets the PDB file loaded into the applet) | ||
| - | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | ||
| - | or leave the SCENE parameter empty for the default display. | ||
| - | --> | ||
{{STRUCTURE_2v3e| PDB=2v3e | SCENE= }} | {{STRUCTURE_2v3e| PDB=2v3e | SCENE= }} | ||
===ACID-BETA-GLUCOSIDASE WITH N-NONYL-DEOXYNOJIRIMYCIN=== | ===ACID-BETA-GLUCOSIDASE WITH N-NONYL-DEOXYNOJIRIMYCIN=== | ||
| - | |||
| - | <!-- | ||
| - | The line below this paragraph, {{ABSTRACT_PUBMED_17666401}}, adds the Publication Abstract to the page | ||
| - | (as it appears on PubMed at http://www.pubmed.gov), where 17666401 is the PubMed ID number. | ||
| - | --> | ||
{{ABSTRACT_PUBMED_17666401}} | {{ABSTRACT_PUBMED_17666401}} | ||
| Line 22: | Line 11: | ||
==See Also== | ==See Also== | ||
| - | *[[Acid beta-glucosidase with N-butyl-deoxynojirimycin|Acid beta-glucosidase with N-butyl-deoxynojirimycin]] | ||
| - | *[[Acid beta-glucosidase with N-nonyl-deoxynojirimycin|Acid beta-glucosidase with N-nonyl-deoxynojirimycin]] | ||
*[[Acid-beta-glucosidase|Acid-beta-glucosidase]] | *[[Acid-beta-glucosidase|Acid-beta-glucosidase]] | ||
*[[Hemagglutinin|Hemagglutinin]] | *[[Hemagglutinin|Hemagglutinin]] | ||
| - | *[[IFG/DG-Cerezyme|IFG/DG-Cerezyme]] | ||
| - | *[[Treatment of Gaucher disease|Treatment of Gaucher disease]] | ||
| - | *[[User:Boris Brumshtein|User:Boris Brumshtein]] | ||
==Reference== | ==Reference== | ||
Revision as of 11:23, 25 July 2012
Contents |
ACID-BETA-GLUCOSIDASE WITH N-NONYL-DEOXYNOJIRIMYCIN
Gaucher disease is caused by mutations in the gene encoding acid beta-glucosidase (GlcCerase), resulting in glucosylceramide (GlcCer) accumulation. The only currently available orally administered treatment for Gaucher disease is N-butyl-deoxynojirimycin (Zavesca, NB-DNJ), which partially inhibits GlcCer synthesis, thus reducing levels of GlcCer accumulation. NB-DNJ also acts as a chemical chaperone for GlcCerase, although at a different concentration than that required to completely inhibit GlcCer synthesis. We now report the crystal structures, at 2A resolution, of complexes of NB-DNJ and N-nonyl-deoxynojirimycin (NN-DNJ) with recombinant human GlcCerase, expressed in cultured plant cells. Both inhibitors bind at the active site of GlcCerase, with the imino sugar moiety making hydrogen bonds to side chains of active site residues. The alkyl chains of NB-DNJ and NN-DNJ are oriented toward the entrance of the active site where they undergo hydrophobic interactions. Based on these structures, we make a number of predictions concerning (i) involvement of loops adjacent to the active site in the catalytic process, (ii) the nature of nucleophilic attack by Glu-340, and (iii) the role of a conserved water molecule located in a solvent cavity adjacent to the active site. Together, these results have significance for understanding the mechanism of action of GlcCerase and the mode of GlcCerase chaperoning by imino sugars.
Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease., Brumshtein B, Greenblatt HM, Butters TD, Shaaltiel Y, Aviezer D, Silman I, Futerman AH, Sussman JL, J Biol Chem. 2007 Sep 28;282(39):29052-8. Epub 2007 Jul 31. PMID:17666401
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
About this Structure
2v3e is a 2 chain structure of Acid-beta-glucosidase and Hemagglutinin with sequence from Homo sapiens. Full crystallographic information is available from OCA.
See Also
Reference
- Brumshtein B, Greenblatt HM, Butters TD, Shaaltiel Y, Aviezer D, Silman I, Futerman AH, Sussman JL. Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease. J Biol Chem. 2007 Sep 28;282(39):29052-8. Epub 2007 Jul 31. PMID:17666401 doi:10.1074/jbc.M705005200
Categories: Glucosylceramidase | Homo sapiens | Aviezer, D. | Brumshtein, B. | Butters, T D. | Futerman, A H. | Greenblatt, H M. | Shaaltiel, Y. | Silman, I. | Sussman, J L. | Acid-beta-glucosidase | Disease mutation | Gaucher disease | Glycoprotein | Glycosidase | Hydrolase | Lipid metabolism | Lysosome | Membrane | N-nonyl-deoxynojirimycin | N-nonyl-deoxynojirimycinalternative initiation | Sphingolipid metabolism
